FIIs have offloaded shares of Bajaj Corp, Nestle, Jyothy Laboratories and Britannia.
For the first time since 2001, promoter stake in BSE 500 decisively below 50%
Anglo-Dutch parent's stake in Indian subsidiary rises from 52.5% to 67.3%.
Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
ITC on Monday said it is conducting more tests on its products at accredited labs across India.
But return on equity deteriorated for 7 of the 12 firms analysed.
Iron-rich noodles and vitamin-rich beverages are some products launched by segment majors
The targeted budget for the project was reportedly projected at 750,000.
What sets 2018 apart from previous years is the magnitude of the shocks that hit our brand ecosystem, says Bharat Bambawale.
While it is difficult to put a number on how much the impact on the ad sales tally could be, it is quite possible the broadcaster will not be able to make its Rs 2-billion target, says Urvi Malvania.
The investigation against HUL was initiated on the basis of an anonymous complaint. It alleged 'profiteering' of around Rs 535 crore between November 15, 2017, and February 28, 2018.
Most offers are coming from regular recruiting firms and sectors led by consulting, analytics, IT and finance.
Advertising taglines such as 'Bright in studies, bright in sports' attempted to drive home the message that Bournvita, a chocolate drink, could build a child's mental and physical faculties.
Sensex rises, Nifty ends at record high; RIL shares rally.
Besides foreign flows, corporate earnings and US Federal Reserve chief Janet Yellen's testimony to the nation's legislature are also likely to impact investor sentiment.
Softening rural consumption and the likelihood of weak corporate earnings in the March quarter saw investors dump stocks.
NPPA suggests expanding the list of essential medicines whose prices are controlled
Surely you have heard them many times over... P V Subramanyam tells you why they are dangerous
With a new campaign for Gatorade and renewed thrust on sports drinks, PepsiCo looks to make the most of the growing passion for fitness in the country.
Some big ones hoard cash unduly and others borrow to keep up payments to shareholders
Analysts are eyeing bigger launches that will positively impact company's fortunes.
Growth in cities has lagged villages as consumers troubled by persistently high inflation have cut spending in the past two years.
Investor lobbies and tax lawyers estimate the bill for international funds and banks could be as high as $8 billion
Markets rebound with financials leading the gains on hopes of a peaceful solution to the turmoil in Ukraine
It also marks the culmination of the revamp exercise that the brand undertook 18 months back, spearheaded by Nellaiappan Thiruambalam, who was appointed as director and CEO of the personal care and foods division in April 2013.
This goes a long way in creating an ethical organisation culture that in turn helps attract talent.
@015 may be a good year for FMCG firms.
The oralcare major has kept its ears firmly to the ground, pushing products into the hinterland and is holding fort in urban India with innovation for continued volume growth.
The benchmark BSE Sensex ended down 2.23 per cent. The Bank Nifty fell 3.59 per cent.
Sensex rises, Nifty holds 8,900; FMCG, Pharma shares lead.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Dilip Shanghvi founded Sun Pharma in 1983.
If you are not happy with the price offered at buybacks, you could be in for a long haul.
India was the flavour of the year, at least in the FMCG sector, as multinationals hiked stakes in their subsidiaries lured by long term potential of the country, while homegrown executives made their way to top hierarchy of global firms in 2013.
FIIs pump in Rs 2,075 crore in past three trading sessions.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances